Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Sanchez L, Leleu X, Beaumont JL, Yu H, Hudgens S, Simonova M, Auner HW, Quach H, Delimpasi S, Špička I, Pour L, Kriachok I, Dimopoulos MA, Usenko G, Hájek R, Benjamin R, Sinha DK, Venner C, Illmer T, Garg MK, Stevens DA, Jagannath S, Levy M, Anderson LD Jr, Bahlis NJ, Facon T, Cavo M, Chai Y, Ma X, Tang S, Leong H, Shah J, Shacham S, Kauffman M, Richardson P, Grosicki S. Sanchez L, et al. Among authors: richardson p. Am J Hematol. 2021 Oct 1;96(10):E383-E386. doi: 10.1002/ajh.26282. Epub 2021 Jul 12. Am J Hematol. 2021. PMID: 34161627 Free article. Clinical Trial. No abstract available.
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. Jagannath S, et al. Among authors: richardson pg. Br J Haematol. 2004 Oct;127(2):165-72. doi: 10.1111/j.1365-2141.2004.05188.x. Br J Haematol. 2004. PMID: 15461622 Free article. Clinical Trial.
International uniform response criteria for multiple myeloma.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. Durie BG, et al. Among authors: richardson p. Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20. Leukemia. 2006. PMID: 16855634
Emerging drugs in multiple myeloma.
Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Ghobrial IM, et al. Among authors: richardson p. Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. doi: 10.1517/14728214.12.1.155. Expert Opin Emerg Drugs. 2007. PMID: 17355220 Review.
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Zangari M, et al. Among authors: richardson p. Am J Hematol. 2007 Sep;82(9):831-3. doi: 10.1002/ajh.20961. Am J Hematol. 2007. PMID: 17546639 Free article.
Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity. Using data from the APEX (Richardson et al., N Engl J Med 2005;352:2487-2498) study, we have assessed the relationship of changes in alkaline phosphatase (ALP) …
Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity. Using data from the APEX ( …
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM. Younes H, et al. Among authors: richardson p. Clin Cancer Res. 2007 Jul 1;13(13):3771-5. doi: 10.1158/1078-0432.CCR-06-2921. Clin Cancer Res. 2007. PMID: 17606706 Review.
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Ghobrial J, et al. Among authors: richardson p. Oncology (Williston Park). 2007 Jun;21(7):785-92; discussion 798-800. Oncology (Williston Park). 2007. PMID: 17722741 Free article. Review.
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.
Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Lacy MQ, et al. Among authors: richardson p. J Clin Oncol. 2008 Jul 1;26(19):3196-203. doi: 10.1200/JCO.2007.15.9319. Epub 2008 May 12. J Clin Oncol. 2008. PMID: 18474873 Clinical Trial.
2,362 results